| Literature DB >> 30031978 |
Lei Wang1, Jing Tang1, Andrew D Huber2, Mary C Casey3, Karen A Kirby4, Daniel J Wilson1, Jayakanth Kankanala1, Michael A Parniak5, Stefan G Sarafianos6, Zhengqiang Wang7.
Abstract
Human immunodeficiency virus (HIV) reverse transcriptase (RT)-associated ribonuclease H (RNase H) remains an unvalidated drug target. Reported HIV RNase H inhibitors generally lack significant antiviral activity. We report herein the design, synthesis, biochemical and antiviral evaluations of a new 6-biphenylmethyl subtype of the 3-hydroxypyrimidine-2,4-dione (HPD) chemotype. In biochemical assays, analogues of this new subtype potently inhibited RT RNase H in low nanomolar range without inhibiting RT polymerase (pol) or integrase strand transfer (INST) at the highest concentrations tested. In cell-based assays, a few analogues inhibited HIV in low micromolar range without cytotoxicity at concentrations up to 100 μM.Entities:
Keywords: 3-Hydroxypyrimidine-2,4-dione (HPD); Human immunodeficiency virus (HIV); Inhibitors; RNase H; Structure-activity-relationship (SAR)
Mesh:
Substances:
Year: 2018 PMID: 30031978 PMCID: PMC6114935 DOI: 10.1016/j.ejmech.2018.07.035
Source DB: PubMed Journal: Eur J Med Chem ISSN: 0223-5234 Impact factor: 6.514